Suppression of TXNIP in CML cells restored glucose uptake and glycolytic rate with was suppressed by imatinib, and subsequently provided a survival advantage and drug resistance of CML cells. Here, TXNIP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.